As environmental issues become ever more pressing, pharmaceutical giant Boehringer Ingelheim is leading a green revolution within its industry, with a special focus on sustainable vaccine production. The company's innovative initiatives extend well beyond the finished vaccine. Boehringer
The University of Delaware is making major strides in the biopharma sector by launching the new SABRE Center. Backed by $45 million in federal funding, including $10 million from the American Rescue Plan, this 90,000-square-foot hub is set to propel the university into a leader in biopharmaceutical
Upstream bioprocessing is pivotal in biomanufacturing, where cellular systems produce vital therapeutic proteins and biological products. This field is experiencing a surge of innovative methods in response to the increased global demand for biopharmaceuticals driven by rising health concerns.
Lantern Pharma's LP-300 signals a significant advancement in the fight against non-small cell lung cancer (NSCLC), particularly in never-smokers—a group seeing elevated incidence rates, notably in East Asia. This promising therapeutic option stands out as NSCLC treatments often overlook the unique
The biopharmaceutical realm is recognized for its revolutionary treatments that transform health outcomes. However, in a shifting economy rife with quicksand-like market dynamics and intricate regulation, simply developing innovative drugs isn't sufficient. These companies are scrutinized for every
In the first three months of 2024, the leaders in the biopharmaceutical sector achieved significant financial success, navigating a tumultuous economic landscape and critical policy shifts with exceptional skill. These companies have not just sustained themselves but also have forged paths of